These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 25944415)

  • 1. Cost to government and society of chronic kidney disease stage 1-5: a national cohort study.
    Wyld ML; Lee CM; Zhuo X; White S; Shaw JE; Morton RL; Colagiuri S; Chadban SJ
    Intern Med J; 2015 Jul; 45(7):741-7. PubMed ID: 25944415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost of diabetes in adults in Australia.
    Lee CM; Colagiuri R; Magliano DJ; Cameron AJ; Shaw J; Zimmet P; Colagiuri S
    Diabetes Res Clin Pract; 2013 Mar; 99(3):385-90. PubMed ID: 23298663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs and healthcare use of patients with chronic kidney disease in the Northern Territory, Australia.
    Chen W; Howard K; Gorham G; Abeyaratne A; Zhao Y; Adegboye O; Kangaharan N; Talukder MRR; Taylor S; Cass A;
    BMC Health Serv Res; 2024 Jul; 24(1):791. PubMed ID: 38982437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The economic burden of progressive chronic kidney disease among patients with type 2 diabetes.
    Vupputuri S; Kimes TM; Calloway MO; Christian JB; Bruhn D; Martin AA; Nichols GA
    J Diabetes Complications; 2014; 28(1):10-6. PubMed ID: 24211091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost of diabetes and obesity in Australia.
    Lee CMY; Goode B; Nørtoft E; Shaw JE; Magliano DJ; Colagiuri S
    J Med Econ; 2018 Oct; 21(10):1001-1005. PubMed ID: 29978743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?
    Kent S; Schlackow I; Lozano-Kühne J; Reith C; Emberson J; Haynes R; Gray A; Cass A; Baigent C; Landray MJ; Herrington W; Mihaylova B;
    BMC Nephrol; 2015 Apr; 16():65. PubMed ID: 25924679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Cardiovascular Disease and Chronic Kidney Disease on Life Expectancy and Direct Medical Cost in a 10-Year Diabetes Cohort Study.
    Wan EYF; Chin WY; Yu EYT; Wong ICK; Chan EWY; Li SX; Cheung NKL; Wang Y; Lam CLK
    Diabetes Care; 2020 Aug; 43(8):1750-1758. PubMed ID: 32457057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kidney involvement in tuberous sclerosis complex: the impact on healthcare resource use and costs.
    Vekeman F; Magestro M; Karner P; Duh MS; Nichols T; van Waalwijk van Doorn-Khosrovani SB; Zonnenberg BA
    J Med Econ; 2015; 18(12):1060-70. PubMed ID: 26201433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The economic implications of treating atherothrombotic disease in Australia, from the government perspective.
    Ademi Z; Liew D; Hollingsworth B; Wolfe R; Steg GP; Bhatt DL; Reid CM;
    Clin Ther; 2010 Jan; 32(1):119-32; discussion 106-7. PubMed ID: 20171418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of chronic kidney disease and comorbid conditions on health care costs: A 10-year observational study in a general population.
    Baumeister SE; Böger CA; Krämer BK; Döring A; Eheberg D; Fischer B; John J; Koenig W; Meisinger C
    Am J Nephrol; 2010; 31(3):222-9. PubMed ID: 20068286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
    Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
    Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-dialysis dependent chronic kidney disease is associated with high total and out-of-pocket healthcare expenditures.
    Small C; Kramer HJ; Griffin KA; Vellanki K; Leehey DJ; Bansal VK; Markossian TW
    BMC Nephrol; 2017 Jan; 18(1):3. PubMed ID: 28056852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. All-cause costs increase exponentially with increased chronic kidney disease stage.
    Golestaneh L; Alvarez PJ; Reaven NL; Funk SE; McGaughey KJ; Romero A; Brenner MS; Onuigbo M
    Am J Manag Care; 2017 Jun; 23(10 Suppl):S163-S172. PubMed ID: 28978205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular readmissions and excess costs following percutaneous coronary intervention in patients with chronic kidney disease: data from a large multi-centre Australian registry.
    Ariyaratne TV; Ademi Z; Duffy SJ; Andrianopoulos N; Billah B; Brennan AL; New G; Black A; Ajani AE; Clark DJ; Yan BP; Yap CH; Reid CM
    Int J Cardiol; 2013 Oct; 168(3):2783-90. PubMed ID: 23643437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A model-based economic evaluation of improved primary care management of patients with type 2 diabetes in Australia.
    Haji Ali Afzali H; Gray J; Beilby J; Holton C; Karnon J
    Appl Health Econ Health Policy; 2013 Dec; 11(6):661-70. PubMed ID: 24243516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inside ANEMIA of CKD: Projecting the Future Burden of Anemia of Chronic Kidney Disease and Benefits of Proactive Management: A Microsimulation Model of the Chinese Population.
    Retat L; Xiao D; Webber L; Martin A; Card-Gowers J; Yao J; Zhang Y; Zhang C; Garcia Sanchez JJ; Cabrera C; Grandy S; Rao N; Wu Y; Li Z; Xuan J
    Adv Ther; 2024 Oct; 41(10):3905-3921. PubMed ID: 39162981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of annual pharmaceutical costs in Australia for community-based individuals with, or at risk of, cardiovascular disease: analysis of Australian data from the REACH registry.
    Ademi Z; Liew D; Hollingsworth B; Steg PG; Bhatt DL; Reid CM;
    Am J Cardiovasc Drugs; 2010; 10(2):85-94. PubMed ID: 20334445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic costs of diabetes in the U.S. In 2007.
    American Diabetes Association
    Diabetes Care; 2008 Mar; 31(3):596-615. PubMed ID: 18308683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health Care Costs by Type of Expenditure across eGFR Stages among Patients with and without Diabetes, Cardiovascular Disease, and Heart Failure.
    Nichols GA; Ustyugova A; Déruaz-Luyet A; O'Keeffe-Rosetti M; Brodovicz KG
    J Am Soc Nephrol; 2020 Jul; 31(7):1594-1601. PubMed ID: 32487562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of diabetes mellitus on healthcare costs in Italy.
    Giorda CB; Manicardi V; Diago Cabezudo J
    Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):709-19. PubMed ID: 22098288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.